Literature DB >> 25442349

Modelling the impact of fractionation on late urinary toxicity after postprostatectomy radiation therapy.

Claudio Fiorino1, Cesare Cozzarini2, Tiziana Rancati3, Alberto Briganti4, Giovanni Mauro Cattaneo5, Paola Mangili5, Nadia Gisella Di Muzio2, Riccardo Calandrino5.   

Abstract

PURPOSE: To fit urinary toxicity data of patients treated with postprostatectomy radiation therapy with the linear quadratic (LQ) model with/without introducing a time factor. METHODS AND MATERIALS: Between 1993 and 2010, 1176 patients were treated with conventional fractionation (1.8 Gy per fraction, median 70.2 Gy, n=929) or hypofractionation (2.35-2.90 Gy per fraction, n=247). Data referred to 2004-2010 (when all schemes were in use, n=563; conventional fractionation: 316; hypofractionation: 247) were fitted as a logit function of biological equivalent dose (BED), according to the LQ model with/without including a time factor γ (fixing α/β = 5 Gy). The 3-year risks of severe urethral stenosis, incontinence, and hematuria were considered as endpoints. Best-fit parameters were derived, and the resulting BEDs were taken in multivariable backward logistic models, including relevant clinical variables, considering the whole population.
RESULTS: The 3-year incidences of severe stenosis, incontinence, and hematuria were, respectively, 6.6%, 4.8%, and 3.3% in the group treated in 2004-2010. The best-fitted α/β values were 0.81 Gy and 0.74 Gy for incontinence and hematuria, respectively, with the classic LQ formula. When fixing α/β = 5 Gy, best-fit values for γ were, respectively, 0.66 Gy/d and 0.85 Gy/d. Sensitivity analyses showed reasonable values for γ (0.6-1.0 Gy/d), with comparable goodness of fit for α/β values between 3.5 and 6.5 Gy. Likelihood ratio tests showed that the fits with/without including γ were equivalent. The resulting multivariable backward logistic models in the whole population included BED, pT4, and use of antihypertensives (area under the curve [AUC] = 0.72) for incontinence and BED, pT4, and year of surgery (AUC = 0.80) for hematuria. Stenosis data could not be fitted: a 4-variable model including only clinical factors (acute urinary toxicity, pT4, year of surgery, and use of antihypertensives) was suggested (AUC = 0.73).
CONCLUSIONS: The unexpected impact of moderate hypofractionation on severe incontinence and hematuria after postprostatectomy radiation therapy may be explained by a bladder α/β value <1 Gy or, radiobiologically more plausible, by introducing a time factor likely to represent a previously hypothesized consequential component of late effect.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 25442349     DOI: 10.1016/j.ijrobp.2014.08.347

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  6 in total

1.  Use of angiotensin converting enzyme inhibitors is associated with reduced risk of late bladder toxicity following radiotherapy for prostate cancer.

Authors:  Sarah L Kerns; Ashley Amidon Morlang; Sharon M Lee; Derick R Peterson; Brian Marples; Hong Zhang; Kevin Bylund; Doug Rosenzweig; William Hall; Kim De Ruyck; Barry S Rosenstein; Richard G Stock; Antonio Gómez-Caamaño; Ana Vega; Paloma Sosa-Fajardo; Begoña Taboada-Valladares; Miguel E Aguado-Barrera; Chris Parker; Liv Veldeman; Valérie Fonteyne; Renée Bultijnck; Christopher J Talbot; R Paul Symonds; Kerstie Johnson; Tim Rattay; Adam Webb; Maarten Lambrecht; Dirk de Ruysscher; Ben Vanneste; Ananya Choudhury; Rebecca M Elliott; Elena Sperk; Carsten Herskind; Marlon R Veldwijk; Tiziana Rancati; Barbara Avuzzi; Riccardo Valdagni; David Azria; Marie-Pierre Farcy Jacquet; Jenny Chang-Claude; Petra Seibold; Catharine West; Michelle Janelsins; Yuhchyau Chen; Edward Messing; Gary Morrow
Journal:  Radiother Oncol       Date:  2022-01-22       Impact factor: 6.280

2.  Comparative toxicity outcomes of proton-beam therapy versus intensity-modulated radiotherapy for prostate cancer in the postoperative setting.

Authors:  Patricia Mae G Santos; Andrew R Barsky; Wei-Ting Hwang; Curtiland Deville; Xingmei Wang; Stefan Both; Justin E Bekelman; John P Christodouleas; Neha Vapiwala
Journal:  Cancer       Date:  2019-09-10       Impact factor: 6.860

3.  Hypofractionated postoperative helical tomotherapy in prostate cancer: a mono-institutional report of toxicity and clinical outcomes.

Authors:  Francesco Cuccia; Gianluca Mortellaro; Vincenzo Serretta; Vito Valenti; Antonella Tripoli; Marina Gueci; Nicoletta Luca; Antonio Lo Casto; Giuseppe Ferrera
Journal:  Cancer Manag Res       Date:  2018-10-29       Impact factor: 3.989

4.  Minimal difference between fractionated and single-fraction exposure in a murine model of radiation necrosis.

Authors:  Andrew J Boria; Carlos J Perez-Torres
Journal:  Radiat Oncol       Date:  2019-08-13       Impact factor: 3.481

5.  Urinary toxicity after salvage re-irradiation for prostate cancer local failure after definitive radiotherapy: a clinical and dosimetric prognostic factors analysis.

Authors:  Giovanna Dipasquale; Thomas Zilli; Claudio Fiorino; Vérane Achard; Michel Rouzaud; Raymond Miralbell
Journal:  J Contemp Brachytherapy       Date:  2022-06-14

6.  Hypofractionated Postprostatectomy Radiation Therapy for Prostate Cancer to Reduce Toxicity and Improve Patient Convenience: A Phase 1/2 Trial.

Authors:  Nolan A Wages; Jason C Sanders; Amy Smith; Songserea Wood; Mitchell S Anscher; Nikole Varhegyi; Tracey L Krupski; Timothy J Harris; Timothy N Showalter
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-11-21       Impact factor: 7.038

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.